Home Views Commentary

Poison pill poisons China trade

Daryl Guppy
Daryl Guppy10/29/2018 7:30 AM GMT+08  • 5 min read
Poison pill poisons China trade
SINGAPORE (Oct 29): Inserted by the US and locked deep down in Chapter 32 of the renegotiated North American Free Trade Agreement is a poison pill. It gives the US veto rights over Canada’s and Mexico’s signing of free trade deals with China, although
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

SINGAPORE (Oct 29): Inserted by the US and locked deep down in Chapter 32 of the renegotiated North American Free Trade Agreement is a poison pill. It gives the US veto rights over Canada’s and Mexico’s signing of free trade deals with China, although the language is couched in terms of “non-market’ economies as defined by the US. It is actually more than a veto, as any China deal would invalidate the new Nafta, allowing the US to unilaterally walk away.

This is not an issue confined to only Canada, the US and Mexico because, if successful, it may act as a template for the way the US proceeds with negotiations with other trade partners.

After decades of supporting China’s integration into the global economy, the US is now focused on disrupting commercial supply chains between Beijing and the US’ foreign partners. This drags previously uninvolved third parties into the dispute and limits their ability to pursue their own interests in trade.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.